Disruption of the NO-sGC-cGMP signaling pathway is central to the pathogenesis of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH), in which endothelial dysfunction leads to impaired NO synthesis. Here, SGCB is linked to endothelial dysfunction.